Research & Development



  阿嬌可能領會錯了意思,一邊拉著長平的手往樓閣里走,一邊道︰“劉家人大多薄情寡義,曹家人呢又是一個短命的,你平時應該多做一些善事,多求求神靈,好保佑曹襄福壽安康。”   還以為這里很空曠,誰知道這里竟然站滿了人!23选5福利彩票   天亮之後,雲瑯就如約來到了長門宮。2014春节彩票休市安排   想了片刻,雲瑯收起了豬嘴,重新把濕布綁在口鼻上,將豬嘴掛在人俑的腰上,咬著牙快速的通過了噴吐著水銀蒸汽的江山社稷圖。   太宰嘆息一聲道︰“你把成蔭君的尸體推下去做什麼,人家是皇族,我還能走的動路。”2014世界杯足球彩票   紅袖的小臉漲得通紅,忍不住仰頭道︰“婢子如今是雲家的婢子,少爺帶我極好,婢子也在這里活的快活,已經快要忘記來家了。”

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo